Trials / Completed
CompletedNCT04796948
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection) | irinotecan liposome in combination with oxaliplatin and 5-FU/LV |
Timeline
- Start date
- 2021-04-08
- Primary completion
- 2024-06-28
- Completion
- 2024-06-28
- First posted
- 2021-03-15
- Last updated
- 2025-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04796948. Inclusion in this directory is not an endorsement.